{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:02:55Z","timestamp":1773478975653,"version":"3.50.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00280-019-03878-3","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:40:59Z","timestamp":1558582859000},"page":"241-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment"],"prefix":"10.1007","volume":"84","author":[{"given":"Vasiliki","family":"Galani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Varouktsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatis S.","family":"Papadatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antigoni","family":"Mitselou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Sainis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Constantopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotanna","family":"Dalavanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"issue":"8","key":"3878_CR1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","volume":"133","author":"AN Husain","year":"2009","unstructured":"Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133(8):1317\u20131331","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"3878_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227(1):44\u201358","journal-title":"J Cell Physiol"},{"issue":"6","key":"3878_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","volume":"142","author":"RL Attanoos","year":"2018","unstructured":"Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL (2018) Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med 142(6):753\u2013760","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"3878_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1378\/chest.121.1.273","volume":"121","author":"V Galani","year":"2002","unstructured":"Galani V, Constantopoulos S, Manda-Stachouli C, Frangou-Lazaridis M, Mavridis A, Vassiliou M et al (2002) Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of \u201cprotection\u201d against neoplasia? Chest 121(1):273\u2013278","journal-title":"Chest"},{"issue":"28","key":"3878_CR5","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C et al (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107(28):12611\u201312616","journal-title":"Proc Natl Acad Sci USA"},{"key":"3878_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","volume":"18","author":"M Carbone","year":"2012","unstructured":"Carbone M, Yang H (2012) Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 18:598\u2013604","journal-title":"Clin Cancer Res"},{"key":"3878_CR7","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904\u20135912","journal-title":"Oncogene"},{"key":"3878_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/path.4133","volume":"229","author":"A Mantovani","year":"2013","unstructured":"Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229:176\u2013185","journal-title":"J Pathol"},{"key":"3878_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49\u201361","journal-title":"Immunity"},{"key":"3878_CR10","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1002\/cncr.26143","volume":"117","author":"BM Burt","year":"2011","unstructured":"Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ (2011) Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 117:5234\u20135244","journal-title":"Cancer"},{"issue":"2","key":"3878_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/pr800370n","volume":"8","author":"DT Archimandriti","year":"2009","unstructured":"Archimandriti DT, Dalavanga YA, Cianti R, Bianchi L, Manda-Stachouli C, Armini A et al (2009) Proteome analysis of bronchoalveolar lavage in individuals from Metsovo, nonoccupationally exposed to asbestos. J Proteome Res 8(2):860\u2013869","journal-title":"J Proteome Res"},{"key":"3878_CR12","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","volume":"36","author":"S Pastorino","year":"2018","unstructured":"Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I et al (2018) A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol 36:3485\u20133494","journal-title":"J Clin Oncol"},{"issue":"28","key":"3878_CR13","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN et al (2018) Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol 36(28):2863\u20132871","journal-title":"J Clin Oncol"},{"issue":"4","key":"3878_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48(4):407\u2013416","journal-title":"Nat Genet"},{"issue":"1\u20134","key":"3878_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10937404.2011.556051","volume":"14","author":"SXL Huang","year":"2011","unstructured":"Huang SXL, Jaurand MC, Kamp DW, Whysner J, Hei TK (2011) Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev 14(1\u20134):179\u2013245","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"12","key":"3878_CR16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jclinpath-2014-202465","volume":"67","author":"M Takeda","year":"2014","unstructured":"Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Nakai T et al (2014) Comparison of genomic abnormality in malignant mesothelioma by the site of origin. J Clin Pathol 67(12):1038\u20131043","journal-title":"J Clin Pathol"},{"issue":"3","key":"3878_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/15384047.2016.1145850","volume":"17","author":"AC Borczuk","year":"2016","unstructured":"Borczuk AC, Pei J, Taub RN, Levy B, Nahum O, Chen J et al (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17(3):328\u2013335","journal-title":"Cancer Biol Ther"},{"key":"3878_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prp.2009.12.002","volume":"206","author":"V Galani","year":"2010","unstructured":"Galani V, Tatsaki E, Bai M, Kitsoulis P, Lekka M, Nakos G et al (2010) The role of apoptosis in the pathophysiology of Acute Respiratory Distress Syndrome (ARDS): an up-to-date cell-specific review. Pathol Res Pract 206:145\u2013150","journal-title":"Pathol Res Pract"},{"issue":"3","key":"3878_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486\u2013541","journal-title":"Cell Death Differ"},{"issue":"4","key":"3878_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc776","volume":"2","author":"FH Igney","year":"2002","unstructured":"Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2(4):277\u2013288","journal-title":"Nat Rev Cancer"},{"key":"3878_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1476-4598-6-66","volume":"6","author":"LL Belyanskaya","year":"2007","unstructured":"Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA (2007) Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 6:66","journal-title":"Mol Cancer"},{"issue":"6","key":"3878_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1165\/rcmb.2004-0355OC","volume":"33","author":"KU Kim","year":"2005","unstructured":"Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z et al (2005) A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33(6):541\u2013548","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"47","key":"3878_CR23","doi-asserted-by":"publisher","first-page":"7753","DOI":"10.1038\/sj.onc.1208051","volume":"23","author":"MR Rippo","year":"2004","unstructured":"Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, Amici G et al (2004) FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 23(47):7753\u20137760","journal-title":"Oncogene"},{"issue":"1","key":"3878_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1165\/ajrcmb.25.1.4472","volume":"25","author":"W Liu","year":"2001","unstructured":"Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC (2001) Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 25(1):111\u2013118","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"3878_CR25","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/sj.bjc.6601707","volume":"90","author":"M Tomasetti","year":"2004","unstructured":"Tomasetti M, Rippo MR, Alleva R, Moretti S, Andera L, Neuzil J et al (2004) Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. Br J Cancer 90(8):1644\u20131653","journal-title":"Br J Cancer"},{"issue":"10","key":"3878_CR26","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1158\/1535-7163.MCT-07-0278","volume":"6","author":"KS Abayasiriwardana","year":"2007","unstructured":"Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB et al (2007) Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther 6(10):2766\u20132776","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"3878_CR27","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.4161\/cbt.8.24.10824","volume":"8","author":"SI Katz","year":"2009","unstructured":"Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W et al (2009) Sorafenib inhibits ERK1\/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther 8(24):2406\u20132416","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"3878_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1165\/rcmb.2009-0206TR","volume":"42","author":"NH Heintz","year":"2010","unstructured":"Heintz NH, Janssen-Heininger YM, Mossman BT (2010) Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 42(2):133\u2013139","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"27","key":"3878_CR29","doi-asserted-by":"publisher","first-page":"10397","DOI":"10.1073\/pnas.0604008103","volume":"103","author":"H Yang","year":"2006","unstructured":"Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103(27):10397\u201310402","journal-title":"Proc Natl Acad Sci USA"},{"issue":"37","key":"3878_CR30","doi-asserted-by":"publisher","first-page":"E3870","DOI":"10.1073\/pnas.1413409111","volume":"111","author":"M Rapha\u00ebl","year":"2014","unstructured":"Rapha\u00ebl M, Lehen\u2019kyi V, Vandenberghe M, Beck B, Khalimonchyk S, Abeele F et al (2014) TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proc Natl Acad Sci USA 111(37):E3870\u2013E3879","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3878_CR31","first-page":"6231","volume":"14","author":"F Li","year":"2017","unstructured":"Li F, Zhu D, Yang Y, Wu K, Zhao S (2017) Overexpression of calcyphosine is associated with poor prognosis in esophageal squamous cell carcinoma. Oncol Lett 14(5):6231\u20136237","journal-title":"Oncol Lett"},{"issue":"21","key":"3878_CR32","first-page":"6065","volume":"62","author":"ME Ramos-Nino","year":"2002","unstructured":"Ramos-Nino ME, Timblin CR, Mossman BT (2002) Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 62(21):6065\u20136069","journal-title":"Cancer Res"},{"key":"3878_CR33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1165\/rcmb.2007-0382OC","volume":"38","author":"CB Manning","year":"2008","unstructured":"Manning CB, Sabo-Attwood T, Robledo RF, Macpherson MB, Rincon M, Vacek P (2008) Targeting the MEK1 cascade in lung epithelium inhibits proliferation and fibrogenesis by asbestos. Am J Respir Cell Mol Biol 38:618\u2013626","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"3878_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/ijc.25763","volume":"129","author":"A Shukla","year":"2011","unstructured":"Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ et al (2011) ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer 129(5):1075\u20131086","journal-title":"Int J Cancer"},{"issue":"21","key":"3878_CR35","doi-asserted-by":"publisher","first-page":"34405","DOI":"10.18632\/oncotarget.14907","volume":"8","author":"L Masuelli","year":"2017","unstructured":"Masuelli L, Benvenuto M, Stefano ED, Mattera R, Fantini M, Feudis GD et al (2017) Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line. Oncotarget 8(21):34405\u201334422","journal-title":"Oncotarget"},{"issue":"3","key":"3878_CR36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/cgt.2011.86","volume":"19","author":"Q Li","year":"2012","unstructured":"Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, Yamauchi S et al (2012) Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesotheliomaand enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 19(3):218\u2013228","journal-title":"Cancer Gene Ther"},{"key":"3878_CR37","first-page":"3508","volume":"5","author":"Y Soini","year":"1999","unstructured":"Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, P\u00e4\u00e4kk\u00f6 P (1999) Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5:3508\u20133515","journal-title":"Clin Cancer Res"},{"key":"3878_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.cgt.7700332","volume":"8","author":"I Mohiuddin","year":"2001","unstructured":"Mohiuddin I, Cao X, Fang B, Nishizaki M, Smythe WR (2001) Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 8:547\u2013554","journal-title":"Cancer Gene Ther"},{"key":"3878_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1067\/mtc.2002.121684","volume":"123","author":"WR Smythe","year":"2002","unstructured":"Smythe WR, Mohuiddin I, Ozveran M, Cao XX (2002) Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 123:1191\u20131198","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"3878_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4161\/cbt.6.2.3626","volume":"6","author":"X Cao","year":"2007","unstructured":"Cao X, Rodarte C, Zhang L, Morgan CD, Littlejohn J, Smythe WR (2007) Bcl2\/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther 6(2):246\u2013252","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"3878_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/ijc.23452","volume":"123","author":"JE Littlejohn","year":"2008","unstructured":"Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L et al (2008) Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer 123(1):202\u2013208","journal-title":"Int J Cancer"},{"issue":"6","key":"3878_CR42","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/carcin\/bgq026","volume":"31","author":"E Varin","year":"2010","unstructured":"Varin E, Denoyelle C, Brotin E, Meryet-Figui\u00e8re M, Giffard F, Abeilard E et al (2010) Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 31(6):984\u2013993","journal-title":"Carcinogenesis"},{"issue":"8","key":"3878_CR43","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/cdd.2009.32","volume":"16","author":"J Daubriac","year":"2009","unstructured":"Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, Renier A et al (2009) Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ 16(8):1146\u20131155","journal-title":"Cell Death Differ"},{"issue":"9","key":"3878_CR44","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1073\/pnas.0712399105","volume":"105","author":"DJ Sugarbaker","year":"2008","unstructured":"Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G et al (2008) Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci USA 105(9):3521\u20133526","journal-title":"Proc Natl Acad Sci USA"},{"key":"3878_CR45","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168:960\u2013976","journal-title":"Cell"},{"issue":"3","key":"3878_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10238-016-0432-3","volume":"17","author":"V Galani","year":"2017","unstructured":"Galani V, Kastamoulas M, Varouktsi A, Lampri E, Mitselou A, Arvanitis DL (2017) IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review. Clin Exp Med 17(3):281\u2013289","journal-title":"Clin Exp Med"},{"issue":"4","key":"3878_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/jir.2016.0094","volume":"37","author":"V Galani","year":"2017","unstructured":"Galani V, Papadatos SS, Alexiou G, Galani A, Kyritsis AP (2017) In vitro and in vivo preclinical effects of type I IFNs on gliomas. J Interferon Cytokine Res 37(4):139\u2013146","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"3878_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1165\/ajrcmb.23.3.4002","volume":"23","author":"TM Hong","year":"2000","unstructured":"Hong TM, Yang PC, Peck K, Chen JJ, Yang SC, Chen YC et al (2000) Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol 23(3):355\u2013363","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10","key":"3878_CR49","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","volume":"110","author":"S Zhou","year":"2014","unstructured":"Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S et al (2014) Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma. Br J Cancer 110(10):2479\u20132488","journal-title":"Br J Cancer"},{"issue":"40","key":"3878_CR50","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A et al (2005) Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40):6080\u20136089","journal-title":"Oncogene"},{"issue":"2","key":"3878_CR51","first-page":"181","volume":"2","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K et al (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2(2):181\u2013188","journal-title":"Mol Med Rep"},{"issue":"5","key":"3878_CR52","doi-asserted-by":"publisher","first-page":"e36856","DOI":"10.1371\/journal.pone.0036856","volume":"7","author":"G Pinton","year":"2012","unstructured":"Pinton G, Manente AG, Angeli G, Mutti L, Moro L (2012) Perifosine as a potential novel anti-cancer agent inhibits EGFR\/MET-AKT axis in malignant pleural mesothelioma. PLoS ONE 7(5):e36856","journal-title":"PLoS ONE"},{"issue":"19","key":"3878_CR53","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.1074\/jbc.M709698200","volume":"283","author":"D Barbone","year":"2008","unstructured":"Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283(19):13021\u201313330","journal-title":"J Biol Chem"},{"issue":"5","key":"3878_CR54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1165\/rcmb.2007-0460OC","volume":"39","author":"SM Wilson","year":"2008","unstructured":"Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ et al (2008) mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 39(5):576\u2013583","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"28","key":"3878_CR55","doi-asserted-by":"publisher","first-page":"25461","DOI":"10.1074\/jbc.M302161200","volume":"278","author":"C Vivo","year":"2003","unstructured":"Vivo C, Liu V, Broaddus VC (2003) c-Jun N-terminal\u00a0kinase\u00a0contributes to apoptotic synergy induced by tumor necrosis factor-related\u00a0apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive\u00a0mesothelioma\u00a0cells. J Biol Chem 278(28):25461\u201325467","journal-title":"J Biol Chem"},{"issue":"11","key":"3878_CR56","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/carcin\/bgm135","volume":"28","author":"SL Holley","year":"2007","unstructured":"Holley SL, Fryer AA, Haycock JW, Grubb SE, Strange RC, Hoban PR (2007) Differential effects of glutathione S-transferase pi (GSTP1) haplotypes on cell proliferation and apoptosis. Carcinogenesis 28(11):2268\u20132273","journal-title":"Carcinogenesis"},{"issue":"3","key":"3878_CR57","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.cyto.2013.01.017","volume":"61","author":"M Kastamoulas","year":"2013","unstructured":"Kastamoulas M, Chondrogiannis G, Kanavaros P, Vartholomatos G, Bai M, Briasoulis E et al (2013) Cytokine effects on cell survival and death of A549 lung carcinoma cells. Cytokine 61(3):816\u2013825","journal-title":"Cytokine"},{"key":"3878_CR58","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2741\/1953","volume":"11","author":"S Fox","year":"2006","unstructured":"Fox S, Dharmarajan A (2006) WNT signaling in malignant mesothelioma. Front Biosci 11:2106\u20132112","journal-title":"Front Biosci"},{"issue":"2","key":"3878_CR59","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ijc.21160","volume":"117","author":"J Mazieres","year":"2005","unstructured":"Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY et al (2005) Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer 117(2):326\u2013332","journal-title":"Int J Cancer"},{"issue":"20","key":"3878_CR60","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1158\/0008-5472.CAN-08-0080","volume":"68","author":"Y Kashiwakura","year":"2008","unstructured":"Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M et al (2008) Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC\/Dickkopf-3-induced apoptosis. Cancer Res 68(20):8333\u20138341","journal-title":"Cancer Res"},{"key":"3878_CR61","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","volume":"9","author":"EB Affar","year":"2018","unstructured":"Affar EB, Carbone M (2018) BAP1 regulates different mechanisms of cell death. Cell Death Dis 9:1151","journal-title":"Cell Death Dis"},{"key":"3878_CR62","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P et al (2018) BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20:1181\u20131192","journal-title":"Nat Cell Biol"},{"key":"3878_CR63","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668\u2013672","journal-title":"Nat Genet"},{"key":"3878_CR64","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022\u20131025","journal-title":"Nat Genet"},{"issue":"1","key":"3878_CR65","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/carcin\/bgu227","volume":"36","author":"F Baumann","year":"2015","unstructured":"Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H et al (2015) Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36(1):76\u201381","journal-title":"Carcinogenesis"},{"key":"3878_CR66","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","volume":"6","author":"M Cheung","year":"2017","unstructured":"Cheung M, Testa JR (2017) BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6:270\u2013278","journal-title":"Transl Lung Cancer Res"},{"key":"3878_CR67","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H et al (2015) High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565\u2013576","journal-title":"J Thorac Oncol"},{"key":"3878_CR68","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","volume":"113","author":"Y Yoshikawa","year":"2016","unstructured":"Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T et al (2016) High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci USA 113:13432\u201313437","journal-title":"Proc Natl Acad Sci USA"},{"key":"3878_CR69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature22798","volume":"546","author":"A Bononi","year":"2017","unstructured":"Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M et al (2017) BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 546:549\u2013553","journal-title":"Nature"},{"key":"3878_CR70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, D\u2019Andrea AD (2017) DNA damage and repair biomarkers of immunotherapy response. Cancer Discov 7:675\u2013693","journal-title":"Cancer Discov"},{"issue":"2","key":"3878_CR71","doi-asserted-by":"publisher","first-page":"E429","DOI":"10.3390\/ijms20020429","volume":"20","author":"A Guazzelli","year":"2019","unstructured":"Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M et al (2019) BAP1 Status Determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment. Int J Mol Sci 20(2):E429","journal-title":"Int J Mol Sci"},{"issue":"15","key":"3878_CR72","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/onc.2015.243","volume":"35","author":"A Napolitano","year":"2016","unstructured":"Napolitano A, Pellegrini L, Dey A, Larson D, Tanji M, Flores EG et al (2016) Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35(15):1996\u20132002","journal-title":"Oncogene"},{"issue":"16","key":"3878_CR73","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","volume":"74","author":"J Xu","year":"2014","unstructured":"Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E et al (2014) Germline mutation of Bap1 accelerates development of asbestos-induced malignantmesothelioma. Cancer Res 74(16):4388\u20134397","journal-title":"Cancer Res"},{"issue":"9","key":"3878_CR74","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","volume":"76","author":"Y Kadariya","year":"2016","unstructured":"Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW et al (2016) Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res 76(9):2836\u20132844","journal-title":"Cancer Res"},{"issue":"2","key":"3878_CR75","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","volume":"76","author":"JA Ohar","year":"2016","unstructured":"Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M et al (2016) Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res 76(2):206\u2013215","journal-title":"Cancer Res"},{"issue":"4","key":"3878_CR76","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","volume":"12","author":"N Leblay","year":"2017","unstructured":"Leblay N, Lepr\u00eatre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S et al (2017) BAP1 is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol 12(4):724\u2013733","journal-title":"J Thorac Oncol"},{"issue":"37","key":"3878_CR77","doi-asserted-by":"publisher","first-page":"59314","DOI":"10.18632\/oncotarget.10653","volume":"7","author":"M Carbone","year":"2016","unstructured":"Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H et al (2016) Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Oncotarget 7(37):59314\u201359321","journal-title":"Oncotarget"},{"issue":"7","key":"3878_CR78","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","volume":"37","author":"PA Zucali","year":"2011","unstructured":"Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L et al (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 37(7):543\u2013558","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3878_CR79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel B, Schmid JA (2013) The complexity of NF-kB signaling in inflammation and cancer. Mol Cancer 12(1):86","journal-title":"Mol Cancer"},{"issue":"8","key":"3878_CR80","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrc2889","volume":"10","author":"M Gyrd-Hansen","year":"2010","unstructured":"Gyrd-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-\u03baB, inflammation and cancer. Nat Rev Cancer 10(8):561\u2013574","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3878_CR81","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2005.02.022","volume":"232","author":"X Sun","year":"2006","unstructured":"Sun X, Guly\u00e1s M, Hjerpe A, Dobra K (2006) Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 232(2):161\u2013169","journal-title":"Cancer Lett"},{"issue":"4","key":"3878_CR82","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/sj.onc.1209809","volume":"26","author":"AC Borczuk","year":"2007","unstructured":"Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA (2007) Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26(4):610\u2013617","journal-title":"Oncogene"},{"issue":"4","key":"3878_CR83","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00280-007-0500-1","volume":"61","author":"GJ Gordon","year":"2008","unstructured":"Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL et al (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61(4):549\u2013558","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3878_CR84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00280-009-1181-8","volume":"66","author":"Y Wang","year":"2010","unstructured":"Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A et al (2010) Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 66(3):455\u2013466","journal-title":"Cancer Chemother Pharmacol"},{"key":"3878_CR85","first-page":"536049","volume":"2014","author":"G Chondrogiannis","year":"2014","unstructured":"Chondrogiannis G, Kastamoulas M, Kanavaros P, Vartholomatos G, Bai M, Baltogiannis D et al (2014) Cytokine effects on cell death and major signaling pathways in LNCaP prostate carcinoma cells. B Biomed Res Int 2014:536049","journal-title":"B Biomed Res Int"},{"issue":"2","key":"3878_CR86","first-page":"27","volume":"59","author":"L Jin","year":"2010","unstructured":"Jin L, Amatya VJ, Takeshima Y, Shrestha L, Kushitani K, Inai K (2010) Evaluation of apoptosis and immunohistochemical expression of the apoptosis-related proteins in mesothelioma. Hiroshima J Med Sci 59(2):27\u201333","journal-title":"Hiroshima J Med Sci"},{"issue":"9","key":"3878_CR87","first-page":"687","volume":"1","author":"C Xia","year":"2002","unstructured":"Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K et al (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1(9):687\u2013694","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3878_CR88","first-page":"453","volume":"29","author":"N Zaffaroni","year":"2007","unstructured":"Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M et al (2007) Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 29(6):453\u2013466","journal-title":"Cell Oncol"},{"issue":"11","key":"3878_CR89","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/jcmm.13182","volume":"21","author":"WQ Zhang","year":"2017","unstructured":"Zhang WQ, Dai YY, Hsu PC, Wang H, Cheng L, Yang YL et al (2017) Targeting YAP in malignant pleural mesothelioma. J Cell Mol Med 21(11):2663\u20132676","journal-title":"J Cell Mol Med"},{"key":"3878_CR90","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.tips.2013.08.006","volume":"34","author":"HW Park","year":"2013","unstructured":"Park HW, Guan KL (2013) Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci 34:581\u2013589","journal-title":"Trends Pharmacol Sci"},{"key":"3878_CR91","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2001-1326-3-22","volume":"3","author":"M Gomez","year":"2014","unstructured":"Gomez M, Gomez V, Hergovich A (2014) The Hippo pathway in disease and therapy: cancer and beyond. Clin Transl Med 3:22\u201333","journal-title":"Clin Transl Med"},{"key":"3878_CR92","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854\u201310858","journal-title":"Proc Natl Acad Sci USA"},{"key":"3878_CR93","first-page":"1227","volume":"55","author":"Y Sekido","year":"1995","unstructured":"Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF et al (1995) Neurofibromatosis Type-2 (Nf2) gene is somatically mutated in mesothelioma but not in lung-cancer. Cancer Res 55:1227\u20131231","journal-title":"Cancer Res"},{"key":"3878_CR94","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T et al (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873\u2013883","journal-title":"Cancer Res"},{"key":"3878_CR95","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","volume":"10","author":"A Miyanaga","year":"2015","unstructured":"Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T et al (2015) Hippo pathway gene mutations in malignant mesothelioma revealed by RNA and targeted exon sequencing. J Thorac Oncol 10:844\u2013851","journal-title":"J Thorac Oncol"},{"issue":"237","key":"3878_CR96","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q et al (2014) Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 6(237):237ra68","journal-title":"Sci Transl Med"},{"issue":"3","key":"3878_CR97","doi-asserted-by":"publisher","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","volume":"6","author":"GA Woodard","year":"2017","unstructured":"Woodard GA, Yang YL, You L, Jablons DM (2017) Drug development against the hippo\u00a0pathway\u00a0in\u00a0mesothelioma. Transl Lung Cancer Res 6(3):335\u2013342","journal-title":"Transl Lung Cancer Res"},{"key":"3878_CR98","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lungcan.2018.10.015","volume":"126","author":"R Tranchant","year":"2018","unstructured":"Tranchant R, Quetel L, Montagne F, De Wolf J, Meiller C, De Koning L et al (2018) Assessment\u00a0of\u00a0signaling\u00a0pathway\u00a0inhibitors\u00a0and\u00a0identification\u00a0of\u00a0predictive\u00a0biomarkers\u00a0in\u00a0malignant\u00a0pleural\u00a0mesothelioma. Lung Cancer 126:15\u201324","journal-title":"Lung Cancer"},{"issue":"12","key":"3878_CR99","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","volume":"23","author":"R Tranchant","year":"2017","unstructured":"Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L et al (2017) Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res 23(12):3191\u20133202","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3878_CR100","doi-asserted-by":"publisher","first-page":"22649","DOI":"10.18632\/oncotarget.15152","volume":"8","author":"L Pellegrini","year":"2017","unstructured":"Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH et al (2017) HMGB1\u00a0targeting by ethyl pyruvate suppresses malignant phenotype of human\u00a0mesothelioma. Oncotarget 8(14):22649\u201322661","journal-title":"Oncotarget"},{"issue":"13","key":"3878_CR101","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","volume":"72","author":"S Jube","year":"2012","unstructured":"Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al (2012) Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Can Res 72(13):3290\u20133301","journal-title":"Can Res"},{"key":"3878_CR102","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","volume":"54","author":"JC Edwards","year":"2006","unstructured":"Edwards JC, Swinson DE, Jones JL, Waller DA, O\u2019Byrne KJ (2006) EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54:399\u2013407","journal-title":"Lung Cancer"},{"issue":"8","key":"3878_CR103","first-page":"3080","volume":"9","author":"S Singhal","year":"2003","unstructured":"Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J et al (2003) Gene expression profiling\u00a0of\u00a0malignant\u00a0mesothelioma. Clin Cancer Res 9(8):3080\u20133097","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03878-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T13:08:26Z","timestamp":1663506506000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03878-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["3878"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03878-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}